Roche and reMYND will make Parkinson's and Alzheimer's drugs

09/7/2010 | Reuters

Roche Holding is collaborating with Belgium's reMYND to develop two of the latter's preclinical compounds, which suppress tau neurotoxicity in Alzheimer's disease and alpha-synuclein neurotoxicity in Parkinson's disease. ReMYND might receive from Roche more than $637 million in milestone fees, plus royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX